BlackRock Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

BlackRock Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$868K	Sell	2,595 -31	-1%	-$9.95K	﹤0.01%	2776
2016 Q3	$789K	Buy	2,626 +299	+13%	+$64.8K	﹤0.01%	2813
2016 Q2	$403K	Buy	2,327 +371	+19%	+$80.8K	﹤0.01%	3157
2016 Q1	$438K	Buy	1,956 +30	+2%	+$8.96K	﹤0.01%	2941
2015 Q4	$1.17M	Buy	1,926 +21	+1%	+$11.5K	﹤0.01%	2478
2015 Q3	$980K	Buy	1,905 +298	+19%	+$199K	﹤0.01%	2610
2015 Q2	$703K	Buy	1,607 +1,147	+249%	+$443K	﹤0.01%	2998
2015 Q1	$166K	Buy	460 +15	+3%	+$5.68K	﹤0.01%	3244
2014 Q4	$160K	Hold	445	–	–	﹤0.01%	3279
2014 Q3	$134K	Buy	445 +2	+0.5%	+$821	﹤0.01%	3283
2014 Q2	$271K	Buy	443 +32	+8%	+$17.2K	﹤0.01%	3207
2014 Q1	$275K	Buy	+411	New	+$243K	﹤0.01%	3185

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Investment Management's TVRD Position: Q4 2016 in Review

BlackRock Investment Management reduced its Tvardi Therapeutics (TVRD) stake by 1.2% in Q4 2016, selling an estimated $9.95K and leaving 2,595 shares worth $868K. The position accounts for ﹤0.01% of the portfolio, ranked #2776.

BlackRock Investment Management first reported a position in TVRD in Q1 2014 and has held it in 12 quarters since. The position peaked at $1.17M in Q4 2015. 101 funds tracked by Wall St. Rank hold TVRD as of Q4 2016.

BlackRock Investment Management held 2,595 shares of Tvardi Therapeutics worth $868K as of Q4 2016.
BlackRock Investment Management sold 31 Tvardi Therapeutics shares in Q4 2016, an estimated $9.95K.
Tvardi Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2776 holding.
BlackRock Investment Management first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Investment Management's Tvardi Therapeutics position peaked at $1.17M in Q4 2015.
101 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.